Urinary Biomarkers and Benign Prostatic Hyperplasia

Tyagi, Pradeep; Wang, Zhou; Yoshimura, Naoki

doi:10.1007/s11884-019-00504-z

Cited by 4 publications

(4 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…The prostate is an immunocompetent organ populated by T lymphocytes; however, physiological factors such as aging and OS, as well as external factors such as lifestyle and exogenous testosterone have been associated with increased inflammatory infiltrate of lymphocytes and macrophages, as well as proinflammatory cytokines. 26 , 30 The degree of inflammation that occurs in BPH has been correlated with increased AR expression, DHT levels, urination and acute urinary retention. 9 , 26 On the other hand, DHT can up‐regulate the expression of the inflammatory factor TNF‐α by stimulating AR in macrophages and increasing inflammation, while inflammation is able to alter the cell proliferation/death state and generate overexpression of AR and induce activation of growth factor signalling pathways, responsible for prostatic cell proliferation and PSA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH

Arias‐Chávez,

Mailloux‐Salinas,

Ledesma Aparicio

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is the most common adenoma in old men. Tomatoes are a rich source of bioactive compounds that, as well as selenium (Se), possess antioxidant and antiproliferative activity. The aim was to evaluate the therapeutic effect of Se in combination with a tomato extract in aged rats with BPH. Aged male Wistar rats were divided in the following groups (n = 10 rats/group): Control (C), BPH, BPH + Finasteride (BPH + F), BPH + Tomato Lipidic Extract (BPH + E), BPH + Selenium (BPH + S) and BPH plus E plus S (BPH + E + S). After 4 weeks of treatment, prostate weight, diuresis, antioxidants enzymes, prooxidants and inflammatory markers, growth factors and androgens were determined. BPH + E + S reduced prostate weight by 59.29% and inhibited growth by 99.35% compared to BPH + F which only decreased weight and inhibited growth by 15.31% and 57.54%, respectively. Prooxidant markers were higher with BPH + F (49.4% higher vs. BPH), but BPH + E + S decreased these markers (94.27% vs. BPH) and increased antioxidant activity. Finally, diuresis was higher with the BPH + E + S combination and markers of inflammation and growth factors were significantly lower with respect to BPH + F. Our findings provide a beneficial and protective therapeutic option of E + S directed against androgens, oxidative stress and inflammation that regulates cell proliferation in the prostate gland.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH

Arias‐Chávez,

Mailloux‐Salinas,

Ledesma Aparicio

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…reported relative abundance of TGF-β1 in urine with concomitant absence in serum for IFN-γ, IL-1β, suggesting interconnection of prostate and urine. 35 It was known that T helper cells (Th) play an important role in the activation or suppression of different immune system components depending on cytokine secretion. Th1 cells support immunity against tumors and infection via cytokines such as IFN-γ, TNF-α, and IL-2 whereas Th2 cells are the producers of IL-4, IL-5, IL-6, and IL-10 as well as could support the humeral immune response.…”

Section: Discussionmentioning

confidence: 99%

Thai traditional massage modulates urinary MCP-1 and relevant inflammatory biomarkers in lower urinary tract symptom patients

Sinsomboon¹,

Kuendee

Naladta

et al. 2023

Journal of Traditional and Complementary Medicine

View full text Add to dashboard Cite

“…Benign prostate hyperplasia, a nonmalignant enlargement of the prostate gland, stands as a common condition that significantly impacts the quality of life of men, particularly as they age (2,3). Recent studies have begun to unravel the complex relationship between BPH and prostatic inflammation, shedding light on how inflammatory processes within the prostate may exacerbate or influence the progression of BPH and its clinical outcomes (4). This emerging perspective is grounded in a growing body of evidence suggesting that prostatic inflammation play a pivotal role in the pathogenesis and symptomatology of BPH (5,6).…”

Section: Introductionmentioning

confidence: 99%

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Mehmood,

Ayaz,

Kakakhel

2024

JHRR

View full text Add to dashboard Cite

Background: Benign prostate hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, prevalently impacts the aging male population, often disrupting the quality of life with its accompanying urinary symptoms. The intersection between BPH and prostatic inflammation has emerged as a focal point in urological research, with inflammation speculated to exacerbate BPH progression and symptoms. Understanding this relationship is pivotal in refining therapeutic approaches and improving patient outcomes. Objective: This study aimed to elucidate the effects of prostatic inflammation on the clinical outcomes of patients with BPH, focusing on symptom progression, treatment efficacy, and long-term complications. Methods: This Study Conducted at Gajju Khan Medical College Swabi, KPK, Pakistan, in the duration from January, 2023 to June, 2023. This prospective cohort study involved 126 men with BPH, categorized into two groups based on the presence (n=63) or absence (n=63) of prostatic inflammation. Data were collected over three years, with assessments including demographic information, clinical histories, and prostate examinations. Primary outcomes measured were the progression of BPH symptoms, urinary function, and prostate size. Secondary outcomes included quality of life, acute urinary retention, the need for surgical intervention, medication efficacy, and long-term complications. Statistical analyses employed included Chi-square tests, t-tests, and ANOVA, with SPSS software. Results: The group with prostatic inflammation showed significantly more severe symptom progression (p < 0.01), impaired urinary function (p < 0.01), and increased prostate size (p < 0.01) compared to the non-inflamed group. Secondary outcomes also favored the non-inflamed group with better quality of life scores (75.2 ± 5.2 vs. 78.8 ± 4.8, p < 0.01), lower rates of acute urinary retention (20.3% vs. 15.5%, p < 0.01). Conclusion: Prostatic inflammation significantly worsens the clinical outcomes of BPH, affecting symptom progression, treatment response, and the likelihood of long-term complications. These findings suggest the need for integrated therapeutic strategies that address both BPH and prostatic inflammation to optimize patient care.

show abstract

Urinary Biomarkers and Benign Prostatic Hyperplasia

Cited by 4 publications

References 101 publications

Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH

Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH

Thai traditional massage modulates urinary MCP-1 and relevant inflammatory biomarkers in lower urinary tract symptom patients

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Contact Info

Product

Resources

About